You are using an outdated browser. Please upgrade your browser to improve your experience.

Tchem
SENP7
Sentrin-specific protease 7

Protein Summary
Description
Protease that deconjugates SUMO2 and SUMO3 from targeted proteins, but not SUMO1. Catalyzes the deconjugation of poly-SUMO2 and poly-SUMO3 chains. Has very low efficiency in processing full-length SUMO proteins to their mature forms. The reversible posttranslational modification of proteins by the addition of small ubiquitin-like SUMO proteins (see SUMO1; MIM 601912) is required for many cellular processes. SUMO-specific proteases, such as SENP7, process SUMO precursors to generate a C-terminal diglycine motif required for the conjugation reaction. They also display isopeptidase activity for deconjugation of SUMO-conjugated substrates (Lima and Reverter, 2008 [PubMed 18799455]).[supplied by OMIM, Jun 2009]
Uniprot Accession IDs
Gene Name
Ensembl ID
  • ENST00000314261
  • ENSP00000313624
  • ENSG00000138468
  • ENST00000348610
  • ENSP00000342159
  • ENST00000394085
  • ENSP00000377647
  • ENST00000394091
  • ENSP00000377651
  • ENST00000394095
  • ENSP00000377655

Symbol
  • KIAA1707
  • SSP2
  • SUSP2
Illumination Graph
Knowledge Table
Most Knowledge About
Knowledge Value (0 to 1 scale)
histone modification site profile
0.83
cell type or tissue
0.7
transcription factor binding site profile
0.68
virus perturbation
0.64
transcription factor
0.57


IDG Development Level Summary
Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 236.56   (req: < 5)
Gene RIFs: 9   (req: <= 3)
Antibodies: 217   (req: <= 50)
Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 236.56   (req: >= 5)
Gene RIFs: 9   (req: > 3)
Antibodies: 217   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 2
Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 24
Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0